PATENT CLAIM ANALYSIS

Application Number: 16182443
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["424", "235100"]

Abstract:
The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

Claim (Index 1):
A method of treating a cancer in a subject in need thereof, the method comprising administering or having administered a therapeutically-effective amount of an immunotherapy-based composition to the subject, wherein the immunotherapy-based composition is obtained from an immunotherapy-based viral delivery system comprising:\n (i) at least one helper plasmid comprising DNA sequences for expressing a functional protein derived from each of a gag, pol, and rev gene; (ii) an envelope plasmid comprising a DNA sequence for expressing a envelope protein capable of infecting a target cell; and (iii) a therapeutic vector comprising:\n at least one encoded shRNA capable of inhibiting production of an enzyme of the mevalonate pathway \n or, \n at least one encoded microRNA capable of inhibiting production of an enzyme of the mevalonate pathway.

Metadata:
- Claim Count in Document: 39.0
- Percentile: 98.0
- Lexical Diversity: 1.15625
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15706481', '16008991', '15849062', '15652080', '15904131']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8382777766871919
- 35 USC 102 Novelty (BERT): 0.6905141800631308
- Combined Prediction Score: 0.8235014170247859
- Mean Citation Score: 733.273308
- Max Citation Score: 763.8657
- Similarity Product: 616.2652715402127

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test